<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390946</url>
  </required_header>
  <id_info>
    <org_study_id>NCC-OSA-1601</org_study_id>
    <nct_id>NCT03390946</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Interval Compressed Regimen Using Four-drugs for Osteosarcoma</brief_title>
  <official_title>Feasibility Study of Interval Compressed Regimen Using Four-drugs for Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Byung-Kiu Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to test the feasibility of four-drug, interval-compressed regimen in
      osteosarcoma.

      Primary objective is to explore the toxicity and mortality related to treatment. Secondary
      objectives are to examine tumor necrosis rates after neoadjuvant chemotherapy, and to
      evaluate the usefulness of circulating cell-free DNA, survivin, or transforming growth
      factor-beta1 levels as well as programmed cell death ligand 1 expression in tumor specimen as
      a predictive or prognostic biomarker in osteosarcoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators will investigate the feasibility of interval compressed
      regimen using four-drugs in newly-diagnosed osteosarcoma patients. Four drugs will be
      adriamycin, high-dose methotrexate, cisplatin, ifosfamide. All these drugs will be given
      preoperatively in an interval-compressed schedule, but postoperatively at a regular interval.
      Neoadjuvant therapy will be composed of two courses, and adjuvant therapy of two or three
      courses depending on necrosis rates following neoadjuvant therapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity determined according to CTCAE</measure>
    <time_frame>Until study completion, an average of 3 years</time_frame>
    <description>treatment-related toxicity (organ dysfunction, neutropenic fever, infection, mortality, et al.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor necrosis rate</measure>
    <time_frame>Until study completion, an average of 3years</time_frame>
    <description>necrosis rate of the excised tumor after neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive or prognostic biomarker</measure>
    <time_frame>Until study completion, an average of 3 years</time_frame>
    <description>Usefulness of circulating cell-free DNA, survivin, transforming growth factor-beta1 levels and programmed cell death 1 expression in tumor specimen as a biomarker</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Osteosarcoma</condition>
  <condition>Feasibility</condition>
  <condition>Treatment Response</condition>
  <condition>Biomarker</condition>
  <arm_group>
    <arm_group_label>four-drug interval-compressed regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions for 'four-drug interval-compressed regimen': Drug: methotrexate, cisplatin, doxorubicin, ifosfamide.
Newly diagnosed oseteosarcoma patients under 40 years are eligible. Neoadjuvant chemotherapy with four drugs in an interval-compressed schedule will be done as a single arm.
Duration of neoadjuvant chemotherapy will be 10 weeks like that of conventional three-drug regimen, although four-drugs are employed in the current protocol.
After tumor resection operation, participants will be divided to poor responder group and good responder group based on 90% necrosis rate of a tumor specimen.
Poor responder group and will be assigned to 'Poor responder group adjuvant chemotherapy' and good responder will be assigned to 'Good responder group adjuvant chemotherapy'.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poor responder group adjuvant chemotherapy</intervention_name>
    <description>Poor responder group (necrosis ≤ 90%)
: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20
B. Resection of tumor
C. Adjuvant chemotherapy
Poor responder group (necrosis ≤ 90%)
week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20
Good responder group (necrosis &gt; 90%)
week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin</description>
    <arm_group_label>four-drug interval-compressed regimen</arm_group_label>
    <other_name>PR adjuvant four-drug interval-compressed regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Good responder group adjuvant chemotherapy</intervention_name>
    <description>Good responder group (necrosis &gt; 90%)
: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin</description>
    <arm_group_label>four-drug interval-compressed regimen</arm_group_label>
    <other_name>GR adjuvant four-drug interval-compressed regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed osteosarcoma patients under age 40 years.

        Exclusion Criteria:

          -  Patients who don't meet the organ function criteria as follows;

               1. renal function : CCr or GFR or eGFR ≥ 70 mL/min/1.73 m2

               2. liver function : AST/ALT ≤ 5 x upper limit, total bilirubin ≤ 1.5 x upper limit
                  of normal for age

               3. cardiac function : shortening fraction ≥ 24% or ejection fraction ≥ 50% (Echo)

               4. lung function : No dyspnea on rest, If dyspnea exists, SpO2 95% or more in room
                  air by pulse oximetry,

               5. hematologic : ANC ≥ 750/uL and platelet ≥ 75,000/uL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-Kiu Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byung-Kiu Park, M.D., Ph.D.</last_name>
    <phone>82-31-920-1240</phone>
    <email>bkpark@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byung-Kiu Park, M.D., Ph.D.</last_name>
      <phone>82-31-920-1240</phone>
      <email>bkpark@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Mi Mi Kwon, RN</last_name>
      <phone>82-31-920-1240</phone>
      <email>rnjsalal@ncc.re.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007 Jan 17;99(2):112-28.</citation>
    <PMID>17227995</PMID>
  </reference>
  <reference>
    <citation>Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5. Epub 2016 Aug 25.</citation>
    <PMID>27569442</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Byung-Kiu Park</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>four-drugs, interval-compression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical data of individual participants can be shared without personal information. Each participating center will submit the clinical data to the principal investigation center, after eliminating personal data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

